Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation...

26
Challenges Investigating and Prosecuting Pharmaceutical Crime UNODC TECHNICAL CONFERENCE ON UNODC TECHNICAL CONFERENCE ON TRAFFICKING IN FRAUDULENT MEDICINES TRAFFICKING IN FRAUDULENT MEDICINES February 14 February 14 - - 15, 2013 15, 2013 Vienna, Austria Vienna, Austria Views offered in this presentation are my own views, and not ne Views offered in this presentation are my own views, and not ne cessarily views of the Department of Justice. cessarily views of the Department of Justice. Linda I. Marks Linda I. Marks Senior Litigation Counsel Senior Litigation Counsel Consumer Protection Branch Consumer Protection Branch Department of Justice Department of Justice (202) 307 (202) 307 - - 0060 0060 [email protected] [email protected]

Transcript of Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation...

Page 1: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

Challenges Investigating and Prosecuting Pharmaceutical Crime

UNODC TECHNICAL CONFERENCE ONUNODC TECHNICAL CONFERENCE ON

TRAFFICKING IN FRAUDULENT MEDICINESTRAFFICKING IN FRAUDULENT MEDICINESFebruary 14February 14--15, 201315, 2013

Vienna, AustriaVienna, Austria

�� Views offered in this presentation are my own views, and not neViews offered in this presentation are my own views, and not necessarily views of the Department of Justice.cessarily views of the Department of Justice.

Linda I. MarksLinda I. Marks

Senior Litigation CounselSenior Litigation Counsel

Consumer Protection BranchConsumer Protection Branch

Department of JusticeDepartment of Justice

(202) 307(202) 307--00600060

[email protected]@usdoj.gov

Page 2: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

DOJ/CONSUMER PROTECTION DOJ/CONSUMER PROTECTION

BRANCH AUTHORITYBRANCH AUTHORITY

�� CPB CPB ““is responsible for criminal and civil is responsible for criminal and civil

litigation and related matters arising litigation and related matters arising

under the Federal Food, Drug, and under the Federal Food, Drug, and

Cosmetic Act (FDCA) and other federal Cosmetic Act (FDCA) and other federal

statutes that protect public health and statutes that protect public health and

safety.safety.””

http://www.justice.gov/civil/cpb/cpb_home.htmlhttp://www.justice.gov/civil/cpb/cpb_home.html

Page 3: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

THE PROBLEMTHE PROBLEM

�� Large quantities of prescription drugs coming in Large quantities of prescription drugs coming in

from from ““CanadaCanada”” and other countries create and other countries create

challenges for Customs and Border Protection & challenges for Customs and Border Protection &

FDA.FDA.

�� ““Prescription drug abuse is the NationPrescription drug abuse is the Nation’’s fastests fastest--

growing drug problem.growing drug problem.”” (United States Office of (United States Office of

National Drug Control Policy, 2011)National Drug Control Policy, 2011)

Page 4: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

THE PROBLEMTHE PROBLEM

�� Trade/B2B sites: anyone with a computer can Trade/B2B sites: anyone with a computer can

now become a drug wholesalernow become a drug wholesaler

Page 5: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

THE PROBLEMTHE PROBLEM

�� Physicians are ordering directly from unlicensed Physicians are ordering directly from unlicensed

brokers/wholesalersbrokers/wholesalers

��Receiving drugs not approved for U.S. Receiving drugs not approved for U.S.

marketmarket

��Receiving drugs not properly stored and Receiving drugs not properly stored and

shippedshipped

��Receiving counterfeitsReceiving counterfeits

Page 6: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

Unapproved/Counterfeit DrugsUnapproved/Counterfeit Drugs

�� Drugs can be counterfeit, unapproved, Drugs can be counterfeit, unapproved,

misbranded:misbranded:

-- Contains API Contains API –– too much/too littletoo much/too little-- Different API (sildenafil vs. tadalafil)Different API (sildenafil vs. tadalafil)-- No APINo API-- Harmful/toxic ingredientsHarmful/toxic ingredients

Page 7: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

Direct Customer OrdersDirect Customer Orders

Page 8: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.
Page 9: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.
Page 10: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

Physicians looking for cheaper

suppliers

UNAPPROVED & COUNTERFEITUNAPPROVED & COUNTERFEIT

Page 11: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.
Page 12: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.
Page 13: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

,Keppra, Anti-epileptic Arimidex, Breast cancer

Aricept, Alzheimer’sCasodex, Prostate cancer

Page 14: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

U.S. Criminal ProsecutionsU.S. Criminal Prosecutions

�� Federal Food, Drug, and Cosmetic Act Federal Food, Drug, and Cosmetic Act

(FDCA), 21 U.S.C. (FDCA), 21 U.S.C. §§ 301 et seq. 301 et seq.

�� Counterfeit drug provisions:Counterfeit drug provisions:

�� Selling, dispensing, or holding for sale Selling, dispensing, or holding for sale

counterfeit drugcounterfeit drug

�� Making, selling, controlling things used to Making, selling, controlling things used to

print/imprint drug, container, or labelingprint/imprint drug, container, or labeling

�� Mimicking a drug mark, stamp, tag or labelMimicking a drug mark, stamp, tag or label

Page 15: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

U.S. Criminal ProsecutionsU.S. Criminal Prosecutions

�� Federal Food, Drug, and Cosmetic Act Federal Food, Drug, and Cosmetic Act

(FDCA), 21 U.S.C. (FDCA), 21 U.S.C. §§ 301 et seq.301 et seq.

�� Misbranded/adulterated drug provisionsMisbranded/adulterated drug provisions

�� MisbrandedMisbranded -- includes false or misleading

labeling

�� AdulteratedAdulterated -- includes differing in strength,

quality, or purity from the standards set forth in an official compendium

Page 16: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

U.S. Criminal ProsecutionsU.S. Criminal Prosecutions

�� FDCA FDCA –– FDASIA AmendmentsFDASIA Amendments�� July 2012: new 20 year maximum term of July 2012: new 20 year maximum term of

imprisonment/$1 million USD fine for imprisonment/$1 million USD fine for knowingly & intentionally adulterating a

drug

� Key element: “reasonable probability of

serious adverse health consequences or death”

Page 17: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

U.S. Criminal ProsecutionsU.S. Criminal Prosecutions

�� Trademark infringement, 18 U.S.C. Trademark infringement, 18 U.S.C. §§ 23202320

�� July 2012: new 20 year maximum term of July 2012: new 20 year maximum term of imprisonment /$5 million USD fine for trafficking imprisonment /$5 million USD fine for trafficking counterfeit drugscounterfeit drugs

�� Mail fraud, wire fraudMail fraud, wire fraud

�� Conspiracy to commit other offensesConspiracy to commit other offenses

�� Money laundering Money laundering –– international monetary international monetary transactionstransactions

Page 18: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

Global ChallengesGlobal Challenges

�� Tracing Tracing moneymoney

�� Phony or shell namesPhony or shell names

�� IntermediariesIntermediaries

�� Bank and wire transfer detailsBank and wire transfer details

Page 19: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

Global ChallengesGlobal Challenges

�� Tracing Tracing packagespackages

�� Phony names/addressesPhony names/addresses

�� False customs declarationsFalse customs declarations

�� Drop shippers/reDrop shippers/re--packagerspackagers

�� MultiMulti--jurisdictional businessesjurisdictional businesses

Page 20: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.
Page 21: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

Global ChallengesGlobal Challenges

��Identification of key playersIdentification of key players

��VOIP telephonesVOIP telephones

��New websitesNew websites

Page 22: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

�� FORMAL REQUESTSFORMAL REQUESTS

�� Mutual Legal Assistance Treaties/Letters Mutual Legal Assistance Treaties/Letters RogatoryRogatory

�� Requests made for bank records, corporate Requests made for bank records, corporate records, erecords, e--mail/server records, phone mail/server records, phone records, identifications, interviewsrecords, identifications, interviews

�� Can take many months, or yearsCan take many months, or years

Global ChallengesGlobal Challenges

Page 23: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

Global ChallengesGlobal Challenges

�� Will foreign country notify account holder?Will foreign country notify account holder?

�� Will foreign country open own investigation?Will foreign country open own investigation?

Page 24: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

Global ChallengesGlobal Challenges

�� OTHER MEANS TO GATHER EVIDENCE:OTHER MEANS TO GATHER EVIDENCE:

�� Tracker warrants Tracker warrants –– ok with foreign country? ok with foreign country? Assistance with surveillance?Assistance with surveillance?

�� Are there informal ways to receive Are there informal ways to receive information?information?

�� Industry assistance: purchasing product, Industry assistance: purchasing product, testing product, identifying subjects, testing product, identifying subjects, introducing agents to subjects; international introducing agents to subjects; international resourcesresources

Page 25: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.

Charging DecisionsCharging Decisions

�� Can we extradite from defendantCan we extradite from defendant’’s country ?s country ?

�� From another country where defendant is found?From another country where defendant is found?

�� Do we have extradition treaty?Do we have extradition treaty?

�� Does foreign country have similar laws? Does foreign country have similar laws?

�� Can we seize assets?Can we seize assets?

Page 26: Challenges Investigating and Prosecuting Pharmaceutical Crime · Linda I. Marks Senior Litigation Counsel Consumer Protection Branch Department of Justice (202) 307 -0060 linda.marks@usdoj.gov.